Abstract
The herpesvirus saimiri (HVS) genome has the capacity to incorporate large amounts of heterologous DNA and can be maintained episomally in many different human cell types. To evaluate the efficacy of HVS-mediated gene transfer into human hemopoietic cells, we investigated the ability of an HVS-based construct, carrying the enhanced green fluorescent protein (EGFP) and neomycin resistance genes, to transduce a variety of human hemopoietic cell lines and primary CD34+ cells. As measured by flow cytometry, the numbers of EGFP+ cells at 2 days postinfection differed between various cell types ranging, from 1.3% for KG1 cells to 56.8% for THP-1 cells. In addition, the expression of EGFP in Jurkat cells was retained at >95% per round of cell division over a period of 6 weeks (comparable with Epstein-Barr virus-derived gene therapy systems). Although the virus was not specifically disabled, no lytic viral mRNAs could be detected in transduced Jurkat cells, and infectious virus could not be detected by sensitive virus recovery assay. We also describe a simple centrifugation method that increases the efficiency of transduction by >100% in some cases and may be generally applicable to other herpesvirus-based vectors for ex vivo gene delivery. Using this technique, we were able to demonstrate a tropism for CD34+/CD14+ cells, transducing 30% of the population. These cells are known to give rise to dendritic cells (the most potent of the antigen-presenting cells), suggesting that the vector could be used to deliver DNA sequences encoding tumor antigens for cancer immunotherapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Stevenson, A., Frolova-Jones, E., Hall, K. et al. A herpesvirus saimiri-based gene therapy vector with potential for use in cancer immunotherapy. Cancer Gene Ther 7, 1077–1085 (2000). https://doi.org/10.1038/sj.cgt.7700210
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.cgt.7700210
Keywords
This article is cited by
-
Recently integrated Alu insertions in the squirrel monkey (Saimiri) lineage and application for population analyses
Mobile DNA (2018)
-
Rhadinovirus vector-derived human telomerase reverse transcriptase expression in primary T cells
Gene Therapy (2010)
-
Efficient infection and persistence of a herpesvirus saimiri-based gene delivery vector into human tumor xenografts and multicellular spheroid cultures
Cancer Gene Therapy (2005)
-
Marker gene transfer into human haemopoietic cells using a herpesvirus saimiri-based vector
Gene Therapy (2005)
-
Regulated and constitutive expression of anti-inflammatory cytokines by nontransforming herpesvirus saimiri vectors
Gene Therapy (2005)